Breast cancer

Drug Name

• A Mechanistic Model of Drug Resistance in ER-Positive, PIK3CA-Mutant Breast Cancer
• ABRAXANE
• AFINITOR
• ANDROXY
• ARIMIDEX
• AROMASIN
• Bioimpedance Spectroscopy May Identify Lymphedema Earlier
• Chemotherapy Could Prime Tumors for PD-1 Blockade
• Clinicians Believe Link Between Breast Pain, Cancer Is Weak
• ctDNA Makes Progress as an Early Treatment Indicator in Breast Cancer
• Cyclophosphamide
• Cyclophosphamide Injection
• Doxorubicin HCl
• Doxorubicin HCl Solution
• ELLENCE
• ESTRACE
• EVISTA
• FARESTON
• FASLODEX
• FDA: Breast Implants Linked to Cancer Can Still Be Sold in US
• FEMARA
• Fixed-Dose Trastuzumab in Early-Stage HER2-Positive Breast Cancer: Unanswered Questions
• Fluorouracil
• Fluoxymesterone
• GEMZAR
• Genetic Testing Underused in Breast, Ovarian Cancer
• HALAVEN
• HERCEPTIN
• HERCEPTIN HYLECTA
• Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer
• High Baseline Inflammatory Biomarker Levels Linked to Shorter OS in mTNBC
• IBRANCE
• Identifying Breast Cancer Subtypes Associated With Late Recurrence
• Immune Biomarkers as Predictors of Response to Checkpoint Blockade in Breast Cancer
• INFUGEM
• Intraoperative Lidocaine May Reduce Breast Cancer Surgery-Associated Neuropathic Pain
• IXEMPRA
• KADCYLA
• Kadcyla Approved as Adjuvant Treatment for HER2-Positive Early Breast Cancer
• KISQALI
• KISQALI FEMARA CO-PACK
• Long-Term HannaH Data Support Subcutaneous Trastuzumab for Breast Cancer
• LYNPARZA TABLETS
• Mammo-Based Deep Learning Model Assesses Breast Cancer Risk
• Megestrol Tablets
• Methotrexate for injection
• Methotrexate injection
• NCI-MATCH: No Objective Responses to Palbociclib in Patients With CCND-Amplified Tumors
• NERLYNX
• New Lesions ID’d on Breast MRI During Treatment Likely Benign
• Pamidronate disodium Injection
• PERJETA
• Personalizing Breast Cancer Tx Could Cut Initial Costs of Care
• Phthalates and Postmenopausal Breast Cancer
• PREMARIN
• Radiotherapy Tied to Lower Recurrence of Early, Hormone-Driven Breast Cancer
• Reducing the Economic Burden of Breast Cancer: Patient-Based Recommendations
• Risk-Based Breast Cancer Screening Guidelines from the American Society of Breast Cancer Surgeons
• SOLTAMOX ORAL SOLUTION
• Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
• TALZENNA
• Tamoxifen
• TAXOL
• TAXOTERE
• TECENTRIQ
• TEPADINA
• Test Predicts Benefit of Chemo in ER+, HER2− Breast Cancer
• Testosterone Enanthate
• The Hidden Privilege of Reference Genomes
• Thiotepa
• Trazimera, a Biosimilar to Herceptin, Gets FDA Approval
• TREXALL
• Tumor Hypoxia and Breast Cancer Risk
• Tumor-Infiltrating Lymphocytes and Prognosis in Early-Stage TNBC
• Two RNA Sequencing Inflammatory Scores as Predictors of Benefit From Pembrolizumab in Advanced Breast Cancer
• TYKERB
• VERZENIO
• Vinblastine for injection
• Vinblastine injection
• VITRAKVI
• VITRAKVI ORAL SOLUTION
• XELODA
• ZOLADEX